Etiology of tricuspid valve disease is a predictor of bradyarrhythmia after tricuspid valve surgery.


Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
07 2019
Historique:
received: 01 02 2019
revised: 25 03 2019
accepted: 28 03 2019
pubmed: 3 4 2019
medline: 15 9 2020
entrez: 3 4 2019
Statut: ppublish

Résumé

The tricuspid valve is situated in close proximity to cardiac conduction tissue and damage to this tissue can affect postoperative rhythm. The aim of this study was to quantify the incidence of pacemaker requirement after tricuspid valve surgery and investigate predictors. Data were collected via our operative data collection system and patient files. All patients who underwent surgical procedures of the tricuspid valve from 2004 until 2017 and lacked a pacemaker preoperatively were included in the study. In our cohort of 505 patients 54 required a pacemaker in the first 50 days after surgery. We calculated a 17.5% (95% confidence interval [CI], 13.5-21.3) risk of pacemaker implantation at 4 years postoperatively. Multivariate analysis identified preoperative active endocarditis (odds ratio 3.17; CI, 1.32-7.65; P = 0.010) and "inadequate pacemaker dependent rhythm" (defined as any intrinsic heart rate below 45 per minute requiring pacing) upon admission to the intensive care unit after surgery (odds ratio 5.924; CI, 2.82-12.44; P = 0.001) as predictors for pacemaker requirement in the first 50 days after surgery. Twenty-six pacemakers (48%) were implanted for atrioventricular block, 16 (30%) for sinus node dysfunction and 12 (22%) for atrial fibrillation. Kaplan-Meier analysis showed no difference in survival between the pacemaker and no pacemaker group. Surgery of the tricuspid valve has a high burden of postoperative pacemaker requirement. Preoperative active endocarditis and the initial postoperative rhythm are predictors. Understanding this allows for better decision-making regarding further medical/device therapy.

Identifiants

pubmed: 30938919
doi: 10.1111/jce.13937
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1108-1116

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Florian E M Herrmann (FEM)

Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany.

Helen Graf (H)

Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany.

Petra Wellmann (P)

Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany.

Sebastian Sadoni (S)

Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany.

Christian Hagl (C)

Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany.

Gerd Juchem (G)

Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH